Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(55)
•••
Comment by frohlir944on Aug 07, 2017 10:58pm
146 Views
Post# 26554931

RE:RE:RE:RE:Message for digitel...

RE:RE:RE:RE:Message for digitel...Beenthere,

i think your your letting your anger and personal feelings get the better of you.( quick test of my theory, if your desire to make JD look bad is bigger  than your desire to make money on the stock, you should probably leave and not hang around here!)

I think that in the end JD and most of us will only have been wrong on the timing of the Bioasis story, and not wrong on the concept.  We have all been making educated guesses based on the available information and in hindsight we were probably optimistic in the timeline of the unfolding of this great story.

let us enjoy the ride that is now starting.  We are fortunate to be involved with a company and a story that 99.9% of the world has no clue about (certainly have not started investing in). We get to be in the story and the investment before everyone else.  We are going to make lots of money because be are smart and or lucky to know before everyone else.

lets enjoy making money together now

thx


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities